奥美沙坦联合苯磺酸氨氯地平治疗原发性高血压的临床观察

目的:观察奥美沙坦联合苯磺酸氨氯地平治疗原发性高血压的疗效及安全性。方法:118例原发性高血压患者随机分为观察组(67例)和对照组(51例)。观察组患者给予奥美沙坦,qd,起始剂量为20 mg/次,视降压情况,剂量可增加至40 mg/次,并给予苯磺酸氨氯地平,qd,5 mg/次;对照组患者仅给予苯磺酸氨氯地平,qd,5 mg/次。两组患者疗程均为6周。观察两组患者临床疗效,治疗前、后的血压(BP)变化及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,两组比较差异有统计学意义(P<0.05);两组患者治疗前舒张压(DBP)、收缩压(SBP)比较差异均无统计学意义(P>0.05),而两组患者治疗后DBP、SBP均显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P<0.05);所有患者不良反应均可耐受,且未见严重不良反应发生。结论:奥美沙坦联合苯磺酸氨氯地平治疗原发性高血压疗效显著,且安全性尚可。

Clinical Observation of Olmesartan Combined with Amlodipine Besylate in the Treatment of Primary Hy- pertension

OBJECTIVE： To observe clinical efficacy and safety of olmesartan combined with amlodipine besylate in the treatment of primary hypertension. METHODS： 118 cases of primary hypertension were randomly divided into observation group （67 cases） and control group （51 cases）. Observation group was given olmesartan, qd, initial dose of 20 mg/time, added to 40 mg/ time according to the condition and amlodipine besylate, qd, 5mg/time; control group was given amlodipine besylate, qd, 5mg/ time. Treatment course of 2 groups lasted for 6 weeks. Clinical efficacies, of the change of BP and the occurrence of ADR were observed in 2 groups. RESULTS： Total effective rate of observation group was significantly higher than that of control group; there was statistical significance （P〈0.05）. DBP and SBP of 2 groups had no statistical significance （P〉0.05）. DBP and SBP of 2 groups were significantly lower than before, and those of observation group were lower than those of control group; there was statistical significance （P〈0.05）. ADR of all patients were tolerable, and no severe ADR was found. CONCLUSIONS： Olmesartan combined with amlodipine besylate is effective and safe in the treatment of primary hypertension.